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Residues in the histone substrate binding sites that differ between the KDM4 and KDM5 subfamilies
were identified. Subsequently, a C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one series was designed to
rationally exploit these residue differences between the histone substrate binding sites in order to
improve affinity for the KDM4-subfamily over KDM5-subfamily enzymes. In particular, residues E169 and
V313 (KDM4A numbering) were targeted. Additionally, conformational restriction of the flexible pyr-
idopyrimidinone C8-substituent was investigated. These approaches yielded potent and cell-penetrant
dual KDM4/5-subfamily inhibitors including 19a (KDM4A and KDM5B Ki¼ 0.004 and 0.007 mM,
respectively). Compound cellular profiling in two orthogonal target engagement assays revealed a sig-
nificant reduction from biochemical to cell-based activity across multiple analogues; this decrease was
shown to be consistent with 2OG competition, and suggests that sub-nanomolar biochemical potency
will be required with C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-one compounds to achieve sub-
micromolar target inhibition in cells.
© 2019 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Human Jumonji C-domain (JmjC) histone lysine demethylases
(KDMs) are Fe(II) and 2-oxoglutarate (2OG)-dependent oxygenases
that demethylate mono-, di-, and trimethyl histone lysine, vassilios.bavetsias@icr.ac.uk
r Masson SAS. This is an open accesubstrates [1,2]. They comprise five subfamilies varying in domain
architecture but sharing awell conserved catalytic site [3]. Since the
reporting of the first JmjC histone lysine demethylase in 2006 [4,5],
the JmjC KDMs have emerged as important players in maintaining
chromatin architecture and regulating transcription [6].
The KDM4 subfamily consists of six members (A-F) that de-
methylate histone tail substrates, most notably di-, and tri-
methylated lysine 9 (H3K9Me3/Me2) and lysine 36 (H3K36Me3/
Me2) on histone 3 [6,7]. As well as the JmjC catalytic domain, KDM4
subfamily enzymes contain a JmjN domain [6]; KDM4A-C also
possess PHD and Tudor methyl-lysine reader domains. It has been
suggested that PHD and Tudor domains could stimulate KDM-ss article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Abbreviations list
Boc tert-butoxycarbonyl
DME 1,2-dimethoxyethane
DIBAL diisobutylaluminium hydride
ESI electrospray ionization
HPLC high performance liquid chromatography
HRMS high resolution mass spectrometry
JmjC Jumonji C
LC liquid chromatography
2OG 2-oxoglutarate
PDB protein data bank
SAR structure-activity relationship
SEM 2-(trimethylsilyl)ethoxymethyl
TFA trifluoroacetic acid
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[8,9]. KDM4 subfamily members have been implicated in a number
of human cancers, including promoting growth and cell survival in
acute myeloid leukemia [10] and as regulators of ER-dependent
breast cancer cell growth [11,12]. High expression of KDM4B in
MYCN-amplified neuroblastomas is associated with poor prognosis
[13], and overexpression of KDM4A is reported to promote site-
specific copy number gain (e.g. 1q12) [14]. In addition, KDM4A is
reported to promote prostate cancer initiation through the tran-
scription factor ETV1 [15].
The human KDM5 subfamily, which consists of four members
(A-D), is structurally the most closely related to the KDM4 sub-
family and also contains a JmjN domain. KDM5 enzymes catalyseFig. 1. Reported KDdemethylation of H3K4Me3/Me2 histone lysine substrates and are
implicated in various types of human cancers [16e18]. A require-
ment for KDM5A has been reported in drug tolerant human tumor
cells [19], while KDM5B and KDM5C have been implicated in breast
[20,21] and prostate cancers [22], respectively. Also Dalvi et al.
recently reported that taxane-platin resistant lung cancer cells
showed hypersensitivity to JIB-04 (a pan-selective JmjC KDM in-
hibitor) and the KDM5/KDM6 subfamily inhibitor GSK-J4 [23].
These findings have generated considerable interest in small-
molecule inhibitors of KDM demethylase functions [24]. Early in-
hibitors of JmjC KDMs, such as the pyridine carboxylic acid-based
analogues 1 and 2 (Fig. 1) [25,26] display pan - JmjC histone
demethylase inhibitory activity, and feature a carboxylic acid which
may hinder cell permeability [27]. More recently, a range of
structurally diverse JmjC KDM inhibitors has been reported with
evidence of selective inhibition of specific KDM subfamilies. For
example, the pyridopyrimidinone derivatives 3 and 4 (Fig. 1) show
selective inhibition of both KDM4 and KDM5 subfamilies over
members of KDM2, 3, or 6 demethylases [28,29]. Compounds 5, 6,
and 7 (Fig.1) selectively inhibit KDM5 subfamily members [30e32],
and compound 8 (Fig. 1) has recently been reported as a potent
KDM4 subfamily inhibitor with promising selectivity [33]. In
addition, a chemoproteomics approach revealed compound 9 as a
selective KDM4 subfamily inhibitor [34]. Covalent inhibitors of
KDM5 subfamily have also been recently reported [35,36]. In
addition, a rhodium(III) complex has been reported as a selective
inhibitor of KDM5A [37].
We previously reported the discovery of C8-substituted pyr-
idopyrimidinones (e.g. 4) as a potent, cell penetrant dual KDM4 and
KDM5 inhibitors [29]. Determination of the crystal structures of the
mono m-Cl counterpart of 4 in complex with both KDM4A and
KDM5B allowed us to identify residue differences in the histoneM inhibitors.
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subfamily inhibition. Herein, we report our efforts to gain selec-
tivity for KDM4 over KDM5 subfamily inhibition by targeting res-
idues V313 (KDM4A) and E169 (KDM4A). We also report our
attempts to reduce the conformational flexibility of the C8-
substituent to improve KDM inhibitory activity and investigate
the impact of such changes on KDM4 versus KDM5 selectivity.
Finally, we demonstrate cell-based target engagement for exemplar
compounds from the 2-OG-competitive pyridopyrimidinone series
and reveal a consistent drop off from in vitro biochemical to cell-
based activity.
2. Chemistry
Compounds 16b-m (Table 1), 17a-g (Table 2), 18b-c (Table 3),
and 19a-d (Table 4) were prepared from key intermediates 10 andTable 1
4-Phenylpiperidine derivatisation: m-Phenyl substitutiona.
Compound X KDM4A
IC50 (mM)
KDM4B
IC50 (mM
16ab Cl 0.102± 0.058 0.031± 0
16b F 0.084±
0.019
0.032±
0.016
16c tBu 0.141 0.049±
0.041
16d OMe 0.212±
0.013
0.067±
0.036
16e 0.178 0.101
16f 0.282 0.145
16g 0.136 0.033±
0.012
16h 0.056 0.027±
0.014
16i 0.088±
0.046
0.047±
0.024
16j 0.083±
0.049
0.019±
0.013
16k 0.259 0.063±
0.023
16l 0.059 0.015
16m 0.038±
0.006
0.008
a Results are mean values of two independent determinations or mean (±SD) for n> 2
b Data taken from reference 29.
c Results are from a single experiment.11 viamethods A and B, respectively as previously described for the
synthesis of closely related analogues (Scheme 1) [29].
The key C4-substituted piperidine intermediates required for
the SN2 displacement or reductive amination reactions to prepare
12b-m, 13a-g, 14b-c, and 15a-d (see Scheme 1) were commercially
available or obtained as shown in Scheme 2. N-Protected tetrahy-
dropyridine-4-boronic acid pinacol ester was reacted with appro-
priately substituted aryl/heteroaryl halides under Pd-catalysed
conditions to provide intermediates 22e-h, 22j, 22l,m, 23a, 23e-g
and 24b,c (Scheme 2). Appropriately substituted aryl/heteroaryl
halides were commercially available or readily synthesised via
standard transformations as detailed in the experimental proced-
ure (see Supporting Information). Reduction of the double bond
followed by the removal of the N-protecting group afforded the
desired C4-substituted piperidines (Scheme 2).
The spirocyclopiperidine 30 required for the synthesis of 19b)
KDM5B
IC50 (mM)
KDM5C
IC50 (mM)
Caco-2 (x106 cm/s)
.012 0.023 0.065 11.80
0.029 0.096 11.63
0.025c 0.063c 4.67
0.023 0.086 not
tested
0.051c 0.156c 10.77
0.066c 0.213c not
tested
0.042c 0.079c not
tested
0.017c 0.059c <1.73
0.021c 0.054c <1.52
0.012 0.030 <0.76
0.048c 0.113c not
tested
0.012c 0.035c <0.92
0.006c 0.014c <1.52
unless specified otherwise.
Table 2
4-Phenylpiperidine derivatisation: p-Phenyl substitutiona.
Compound X KDM4A
IC50 (mM)
KDM4B
IC50 (mM)
KDM5B
IC50 (mM)
KDM5C
IC50 (mM)
Caco-2 (x106 cm/s)
17a 0.218 0.153 0.146 0.896b not
tested
17b 0.131 0.024±
0.018
0.080 0.246 2.29
17c 0.068 0.032 0.127b 0.549b <1.81
17d 0.188±
0.063
0.079±
0.033
0.081b 0.313b not
tested
17e 0.077±
0.007
0.018±
0.006
0.026b 0.053b <0.55
17f 0.093 0.020±
0.011
0.012 0.048 <0.76
17g 0.103 0.020±
0.009
0.041 0.108 <1.52
a Results are mean values of two independent determinations or mean (±SD) for n> 2 unless specified otherwise.
b Results are from a single experiment.
Table 3
4-Phenylpiperidine derivatisation: 3,5-phenyl substitutiona.
Compound X Y KDM4A
IC50 (mM)
KDM4B
IC50 (mM)
KDM5B
IC50 (mM)
KDM5C
IC50 (mM)
Caco-2 (x106 cm/s)
18ab CF3 H 0.128 0.039 0.018 0.070 15.31
18b CF3 0.071 0.033±
0.015
0.017 0.038 <0.76
18c CF3 0.246±
0.146
0.102±
0.062
0.032c 0.096c <0.76
a Results are mean values of two independent determinations or mean (±SD) for n> 2 unless specified otherwise.
b Data taken from reference 29.
c Results are from a single experiment.
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Table 4
Pyrazole C4-substituent: Conformational restrictiona.
Compound R KDM4A
IC50 (mM)
KDM4B
IC50 (mM)
KDM5B
IC50 (mM)
KDM5C
IC50 (mM)
Caco-2 (x106 cm/s)
19a 0.100±
0.041
0.043±
0.021
0.038 0.123 11.64
19b 0.143±
0.056
0.045 0.114 0.214 18.06
19c 0.184±
0.069
0.057 0.123b 0.470b 4.25
19d 0.107±
0.020
0.029±
0.006
0.014b not
tested
13.33
a Results are mean values of two independent determinations or mean (±SD) for n> 2 unless specified otherwise.
b Results are from a single experiment.
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lithium bis(trimethylsilyl)amide and tert-butyl bis(2-chloroethyl)
carbamate followed by the hydrogenation of the double bond in 29,
and finally, removal of the Boc protecting group under acidic con-
ditions (Scheme 3).Scheme 1. aReagents and conditions: (a) (i) methanesulfonic anhydride, anhydrous
CH2Cl2, 0 C, 15min, work-up, (ii) triethylamine, C4-substituted piperidine, anhydrous
DMF, 50 C, 15 h; (b) C4-substituted piperidine, anhydrous 1,2-dichloroethane or
CH2Cl2, NaBH(OAc)3, room temp.; (c) 6M HCl, THF, 50e60 C, 3e8 h or 4M HCl in
dioxane, H2O, 50 C.Access to conformationally constrained pyrazole-C4 compounds
34b-h (Scheme 4, Table 5) was achieved by reductive amination of
the relevant aldehyde by piperidine derivative 31 followed by the
introduction of the substituted pyrazole moiety 32 at the C8-
pyridopyrimidinone position via a SNAr displacement reaction,Scheme 2. aReagents and conditions: (a) aryl/heteroaryl halide, Pd(dppf)Cl2, DME, 1M
aqueous Na2CO3, microwave, 120 C, 45min; (b) (i) Pd(OH)2 on carbon, EtOH, 1M HCl,
H2, room temp 1 h or 10% Pd/C, EtOH, H2, room temp, 2 h, (ii) when R¼ Boc: 4M HCl in
dioxane, room temp, 2 h or when R¼ Cbz: AcOH, 10% Pd/C, H2, room temp, 4e6 h.
Scheme 3. aReagents and conditions: (a) (i) LiN(SiMe3)2 (1M solution in THF), THF,
0 C, 45min, (ii) tert-butyl bis(2-chloroethyl)carbamate, 0 C, 2 h; (b) 10% Pd/C, EtOH,
H2, room temp, 2 h; (c) 4M HCl in dioxane, room temp, 2 h.
Scheme 4. aReagents and conditions: (a) aldehyde, NaBH(OAc)3, DMF, room temp, stirring up to 6 h; (b) Cs2CO3, anhydrous MeCN, 8-chloro-3-((2-(trimethylsilyl)ethoxy)methyl)
pyrido[3,4-d]pyrimidin-4(3H)-one, reflux, 18 h; (c) 6M HCl, THF, 50e60 C, 3e8 h.
Table 5
Pyrazole C4-substituent: Conformational restrictiona.
Compound R KDM4A
IC50 (mM)
KDM4B
IC50 (mM)
KDM5B
IC50 (mM)
KDM5C
IC50 (mM)
Caco-2 (x106 cm/s)
34a Me 2.06 0.82 0.156 0.163 <0.76
34b Et 0.693±
0.231
0.455±
0.037
0.149 0.081b <0.76
34c 0.848±
0.234
0.504±
0.072
0.439 0.566 not
tested
34d 1.06 0.497 0.601b 0.856b not
tested
34e 0.756 0.372 0.447b 0.571b <0.76
34f 0.559±
0.152
0.248±
0.048
0.134 0.202b 5.46
34g 0.613 0.302 0.068b 0.132b 2.12
34h 2.41 0.573 0.131b 0.377b not
tested
a Results are mean values of two independent determinations or mean (±SD) for n> 2 unless specified otherwise.
b Results are from a single experiment.
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(Scheme 4).
Preparation of 1-methyl-4-(1H-pyrazol-4-yl)piperidine (37),
required for the synthesis of 34a (Table 5) was carried out using an
alternative approach whereby 4-bromopyrazole (35) was reacted
with nBuLi followed by the addition of 1-methylpiperidin-4-one.
Subsequent dehydration of the addition product under acidic
conditions followed by hydrogenation of the double bond in 36
afforded 37 (Scheme 5). The incorporation of the piperidine 37 atthe C8-pyridopyrimidinone position was achieved via a SNAr
displacement reaction as described for analogues 33b-h (Scheme
4), and the SEM protecting group was removed by treatment
with TBAF in THF.
Access to 41, a matched-pair inactive control for 19a, was ach-
ieved upon treatment of the mesylate 38, prepared as previously
described [38], with spirocyclopiperidine 39 and triethylamine in
DMF followed by the removal of the SEM protecting group of 40
under acidic conditions (Scheme 6).
Scheme 6. aReagents and conditions: (a) triethylamine, anhydrous DMF, 50 C, 15 h; (b) 6M HCl, THF, 50 C, 3 h.
Fig. 2. Overlay of crystal structures of 16a bound to KDM4A (light orange), and KDM5B (cyan). Compound 16a is shown in ball and stick representation and protein backbone chains
are represented as cartoon tubes, with key amino acid side-chains displayed in line representation. Metal ions are shown as spheres. Labels highlight residues that are different
between KDM4A (black) and KDM5B (cyan). KDM5B loop 91e100 is not displayed due to its construct-derived artefactual position as discussed in Fig. S1. (For interpretation of the
references to colour in this figure legend, the reader is referred to the Web version of this article.)
Scheme 5. aReagents and conditions: (a) (i) 2.5M nBuLi in hexane, THF, 78 C to room temp (1.5 h) then cool to78 C, (ii) 1-methylpiperidin-4-one, warm up to room temp, 1.5 h,
then AcOH/TFA, 90 C, 4 h; (b) 10% Pd/C, EtOH, 1M HCl, H2, 16 h.
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We recently reported a series of C8-substituted pyridopyr-
imidinone derivatives, with themost advanced analogues, such as 4
(Fig. 1) and 16a (Table 1), demonstrating selective and equipotent
inhibition of KDM4 and KDM5 over the KDM2, KDM3, and KDM6
subfamilies [29].
To identify potential interactions that could increase KDM4subfamily potency and selectivity over KDM5 subfamily enzymes,
we determined the crystal structures of 16a in complex with
KDM4A and KDM5B (Fig. 2). In the KDM4A-bound structure, the
C4-pyrazole substituent of 16a extends into the histone substrate
binding site and towards the surface of the enzyme (Fig. S2); them-
Cl substituent on the phenyl group makes hydrophobic contact
with V313 of KDM4A (Fig. 2), a residue that is conserved across all
KDM4 subfamily members (Fig. S3). We postulated that this
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increased KDM4 inhibitory profile of 16a compared to the KDM5-
preferring profile of earlier analogues in this series [29]. In addi-
tion,16a is amore potent inhibitor of both KDM4A and KDM4B than
its unsubstituted phenyl counterpart (compound 54g in reference
29) consistent with the observed hydrophobic interaction of them-
Cl substituent. Furthermore, the crystal structure of 16a bound to
KDM5B indicated no residue equivalent to KDM4A V313 due to a
different protein fold (Fig. 2). This observation further supports the
hypothesis that the hydrophobic contact of the m-Cl substituent in
16a with V313 increases KDM4 inhibitory activity leading to a
balanced KDM4/5 inhibitory profile.
A more detailed study of the 16a-bound KDM5B crystal struc-
ture revealed additional residues close to the m-chlorophenyl
moiety of the bound inhibitor that could be exploited to enhance
KDM4-subfamiliy selectivity (Fig. 2). For example, C480 is a serine
residue in all other KDM5 subfamily members, and a glutamate in
the KDM4 subfamily (E169 in KDM4A, Fig. 2, S3 and S4). This
suggests a potential for differential KDM4 versus KDM5 targeting
although we recognised that exploiting selective interaction with
the side chain of E169 (KDM4A numbering) might be challenging
due to its solvent exposed location and high mobility; for example,
the side chain of E169 could not be associated to any electron
density in the 16a-bound KDM4A crystal structure. W486 in
KDM5B is conserved across the KDM5 subfamily whilst the
equivalent residue in the KDM4 subfamily is a tyrosine (Y175 in
KDM4A, Fig. 2, S3 and S4). However, the potential to exploit this
difference is limited due to the similarity of tryptophan and tyro-
sine residues. We also observed that A430 in KDM5B is an aspar-
agine residue in KDM4A (N137, Fig. 2). However, these residues are
not conserved within their respective subfamilies. N137 in KDM4A
corresponds to S138 in KDM4B, S141 in KDM4D, and N139 in
KDM4C (Fig. S3), whilst A430 in KDM5B corresponds to S414 in
KDM5A, and to H445/H435 in KDM5C and KDM5D, respectively
(Fig. S4), rendering exploitation of such differences for KDM4 over
KDM5 subfamily selective inhibition challenging.
Based on these structural insights, we decided to further explore
the favourable hydrophobic contact with V313 (KDM4A) to increaseFig. 3. A) Overlay of crystal structures of 1 (2,4-PDCA, blue, PDB 2VD7) and 16a (beige) bound
(cyan) bound to KDM5B. Metal ions are shown as spheres. Protein backbone chains are repre
(2,4-PDCA) and 16a are shown in ball and stick representation. KDM5B loop 91e100 is not
interpretation of the references to colour in this figure legend, the reader is referred to theaffinity and selectivity for the KDM4 over KDM5 subfamily. As an
alternative approach, we also considered the introduction of a basic
substituent at either the m- or p-position of the phenyl ring in 16a
to target E169 (KDM4A). We recognised that achieving selective
KDM4-over KDM5-subfamily inhibition may be challenging due to
protein flexibility in the histone substrate binding site, as exem-
plified by induced-fit movement observed in C8-substituted pyrido
[3,4-d]pyrimidin-4-one-bound KDM4A and KDM5B crystal struc-
tures compared with small 2OG-competitive inhibitors such as 1
(Fig. 3). For example, the pyrazole C4-substituent in 16a induces
movement of Y175 and nearby loop 160e171 of KDM4A, such that
residues 162e169 become toomobile to be observed in the electron
densitymap. In the KDM5B-16a crystal structure,W486 and nearby
loop 426e435 are displaced relative to the corresponding com-
pound 1-bound structure, and an alternative conformation is
observed for residues 479e482. We also recognised that confor-
mational flexibility of the ligand pyrazole C4-substituent may
adversely impact KDM inhibition and subfamily selectivity.
Both fluoro and tert-butyl substitutions (compounds 16b and
16c, respectively) resulted in similar KDM inhibitory activities to
those observed for them-Cl counterpart 16a (Table 1). Themethoxy
and isopropyl derivatives 16d and 16e proved marginally inferior
KDM4 subfamily inhibitors compared to 16a, and a similar trend
was also observed with the introduction of a bulkier alkoxy sub-
stituent (16f, Table 1).
The introduction of 6-membered heterocyclic substituents
(compounds 16g-i) was tolerated but with no evidence for selective
KDM4 subfamily inhibition (Table 1). Some of the most active in-
hibitors incorporated a basic substituent at the m-position of the
phenyl ring; notably pyrrolidine and dimethylamino derivatives 16j
and 16m, respectively (Table 1). Consistent with previous findings
[29], these m-substituted analogues retained selectivity over other
KDM subfamilies; for example, 16j displayed weaker inhibition of
KDM2A (IC50¼1.97 mM), KDM3A (IC50¼1.85 mM), and KDM6B
(IC50¼ 32.26 mM). Likewise, 16b displayed selectivity over KDM2A
(IC50¼ 4.68 mM), KDM3A (IC50¼ 6.42 mM), and KDM6B
(IC50> 100 mM). The crystal structure of 16m bound to KDM4A
confirmed a direct but suboptimal interaction between the aminoto KDM4A. B) Overlay of crystal structures of 1 (2,4-PDCA, orange, PDB 5A3W) and 16a
sented as cartoon tubes, key residues are displayed in line representation. Compounds 1
displayed due to its construct-derived artefactual position as discussed in Fig. S1. (For
Web version of this article.)
Fig. 4. Overlay of crystal structures of 16m (green) and 16a (beige) bound to KDM4A. Protein backbone chains are represented as cartoon tubes, key residues are displayed in line
representation. Compounds 16m and 16a are shown in ball and stick representation. The two methyl groups in 16m have not been modelled due to too weak density linked to the
high mobility of the corresponding atoms. Metal ions are shown as spheres. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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(distance of 3.2Å, Fig. 4), consistent with the improved KDM4A
potency of 16m (0.038 mM) compared to the unsubstituted parent
(54g in reference 29; KDM4A IC50¼ 0.456 mM). Overall, 16m shows
a balanced KDM4/KDM5 subfamily inhibitory profile whereas the
unsubstituted parent compound (54g in reference 29; KDM5B
IC50¼ 0.058 mM) is KDM5B preferring. However, direct interaction
of the basic substituent with KDM4A E169 was not observed by X-
ray crystallography, likely due to the high mobility of the E169 side
chain observed in all crystal structures (no electron density
detected). Compounds bearing a lipophilic piperidine 4-substituent
(16b, 16c, and 16e) displayed moderate cell permeability (Caco-2
assay, A to B flux) similar to that of 16a (Table 1). However, the
introduction of a heteroaromatic ring (16h and 16i), or the inclusion
of an additional basic centre (16j, 16l, and 16m) had a detrimental
effect on cell permeability (Table 1).
We subsequently investigated the effect of selected p-sub-
stituents on the 4-phenylpiperidine moiety. The presence of a 6-
membered heterocycle (17a-c, Table 2) or alkyl chains bearing a
basic centre (17e and 17f, Table 2) elicited a KDM4/5 inhibitory
profile similar to their m-substituted counterparts with no evi-
dence of clear selective KDM4 over KDM5 inhibition (Tables 1 and
2). However, selectivity for dual KDM4/5 inhibition over other KDM
subfamilies was maintained; for example 17f displayed a weaker
inhibitory activity against KDM2A (IC50¼1.42 mM), KDM3A
(IC50¼ 2.02 mM), and KDM6B (IC50¼ 52.41 mM).
Crystal structures of 17b, 17e and 17f bound to KDM4A
confirmed that the phenyl p-substituent points towards the solvent
accessible region without making any specific contact with the
protein including the targeted residue E169 (Fig. 5). More precisely,
the p-substituents of both 17b and 17e could not be associated with
any electron density, suggesting high mobility and lack of stabili-
sation by the protein. In the 17f-bound KDM4A structure, the p-dimethylamino moiety points towards the solvent accessible re-
gion, but without clear interactions with the protein (Fig. 5).
Similarly to the m-substituted analogues (Table 1), p-substituted
compounds displayed significantly lower permeability in the Caco-
2 assay (A to B flux) relative to that of 16a (Table 2). This drop in
cellular permeability is consistent with increased polarity and/or
the presence of a basic nitrogen.
Noting that both m-chloro, -fluoro, -trifluoromethyl [29] sub-
stituents, and alkyl chains bearing basic centres at them-position of
the distal phenyl ring (Table 1) impart potent and balanced KDM4/5
subfamily inhibition, and also that their binding modes are
potentially complementary (see overlay of 16a and 16m, Fig. 4), we
combined these two substituents in a small series of 3,5-
disubstituted phenyl derivatives (Table 3). Synthesis of the most
desired compounds with both m-Cl and m-alkylamino side chains
proved challenging due to competing dehalogenation upon
reduction of the piperidine double bond (Scheme 2). Nevertheless,
we were able to combine a m-CF3 substituent with basic func-
tionality in the remaining m-position (18b,c; Table 3). This
approach led to potent dual KDM4 and KDM5 inhibition but no
additive inhibitory effect was observed (Table 3), and the KDM4/5
inhibitory profile was broadly similar to that observed with the
corresponding mono-substituted analogues (Tables 1 and 3). We
subsequently solved the structure of 18a bound to KDM4A (Fig. 6).
This structure indicated that the pendant phenyl ring is rotated
such that the m-CF3 substituent does not form an interaction with
V313 in contrast to its m-Cl counterpart (compare Figs. 2, 4 and 6).
This observation could partly explain the lack of additive SAR in
compounds 18b and 18c, assuming that the m-CF3 substituent in
these 3,5-disubstituted phenyl derivatives occupies the same po-
sition as observed for 18a. Compounds 18b and 18c maintained a
selective inhibition profile versus other KDM subfamily members;
for example, 18b displayed weaker inhibitory activity against
Fig. 5. Overlay of crystal structures of 17b (pink), 17e (magenta) and 17f (light-green) bound to KDM4A. Zn(II) atoms are shown as grey spheres. Protein backbone chains are
represented as cartoon tubes, key residues are displayed in line representation. The pyridyl ring in 17b has not been modelled due to too weak density of the corresponding atoms.
Compounds 17b,17e and 17f are shown in ball and stick representation. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version
of this article.)
Fig. 6. Overlay of crystal structures of 18a (brown) and 16a (beige) bound to KDM4A. Zn(II) atoms are shown as grey spheres. Proteins backbone chains are represented as cartoon
tubes, key residues are displayed in line representation. Compounds 18a and 16a are shown in ball and stick representation. (For interpretation of the references to colour in this
figure legend, the reader is referred to the Web version of this article.)
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Fig. 7. Overlay of crystal structures of 19a (grey) and 16a (beige) bound to KDM4A. Zn(II) atoms are shown as spheres. Protein backbone chains are represented as cartoon tubes, key
residues are displayed in line representation. Compounds 19a and 16a are shown in ball and stick representation.
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(IC50¼ 23.97 mM). However, both 18b and 18c displayed low Caco-2
permeability (A to B flux) in line with previous results obtained
with compounds bearing a basic substituent on the phenyl ring
(Tables 1 and 2).
We next turned our attention to constraining the C4-pyrazole
substituent in order to maintain contact with V313 whilst mini-
mising the entropic cost associated with ligand binding. We
envisaged that the lipophilic contact with V313 (KDM4A) (Fig. 2)
could be optimised by conformational restriction directing the
phenyl ring towards V313. This hypothesis led to synthesis of the
spirocyclic analogue 19a which inhibited KDM4 and KDM5 sub-
family members with IC50 values similar to those observed with
16a (Tables 1 and 4). 19a also displayed selective inhibition of
KDM4/5 over other KDM subfamilies, inhibiting KDM2A, KDM3A,
and KDM6B with IC50 values of 4.50, 5.78 and 90.22 mM,
respectively.
The crystal structure of 19a bound to KDM4A (Fig. 7) revealed a
binding mode similar to that of 16a, with the phenyl ring of the
spirocyclic system slightly closer to the side chain of V313 than in
16a (closest phenyl carbon atom is 3.7Å from the side chain of V313
for 19a, versus 4Å for the corresponding carbon in 16a). In the 19a-
bound KDM4A crystal structure, we also observed that a loop
comprising KDM4A residues 308e313 folds over the conforma-
tionally restricted spirocyclic phenyl ring to elicit favourable hy-
drophobic stacking interactions with both Ca and Cb atoms of D311.
In addition, we also observed electron density for the main chain
and Cb of E169 below the spirocyclic phenyl ring of 19a  inter-
estingly, E169 is not commonly visible due to both main chain and
side chain flexibility. Further, the pyrazole C4-substituent in 19a is
associated with a stronger electron density than for the corre-
sponding 16a structure, and is well defined in all four chains of the
asymmetric unit with B factors significantly lower than for the
corresponding atoms in 16a (average B factors of the terminalphenyl in 19a is 0.8 times the average B factor for the whole
structure, while it was 1.3 times for 16a). These observations sug-
gest that 19a is more stably bound in the active site of KDM4A than
16a. Compounds 19b and 19c gave no improvement to KDM4/5
inhibitory profiles relative to 19a (Table 4); however, comparison of
the structures of 19a and 16a bound to KDM4A (Fig. 7) prompted us
to introduce a methyl group at the piperidine C4-position in 16a to
restrict the conformation without a spirocyclic ring system. Pleas-
ingly,19d (Table 4) exhibited a KDM4/5 inhibitory profile similar to
that observed with 19a and the crystal structure of 19d bound to
KDM4A revealed the m-Cl phenyl substituent in an equatorial po-
sitionwith the Cl atommaking contact with V313 (distance of 3.5 Å,
Fig. 8). However, the pyrazole C4-substituent appeared less well
stabilised than its equivalent in 19a (the full substituent is seen only
in one chain for 19d, and with B factors up to 1.3 times higher than
the average of the structure). This may arise from freedom of
rotation around the piperidine C4-bond in 19d and 16a compared
to the constrained spirocyclic compound 19a. Satisfyingly, all ana-
logues in this subseries displayed good permeability in the Caco-2
assay (A to B flux; Table 4).
In a further attempt to restrict the conformation of the C4-
pyrazole substituent, we directly attached the N-methylpiperidin-
4-yl moiety to C4 of the pyrazole to give 34a, a more potent in-
hibitor of KDM5 relative to KDM4 subfamily enzymes by at least 5-
fold (Table 5). A crystal structure of 34a in complex with KDM4A
(Fig. 9) revealed electron density for the pyrazole substituent in all
four chains of the asymmetric unit, with the piperidine nitrogen
closer to the side chain carboxylate of D191 than with 16a (2.9 Å
versus 4.5 Å for 16a). In contrast to the 16a-KDM4A structure, the
loop comprising residues 160e171 remained in the conformation
observed in the apoprotein structure and no movement was
observed for Y175. Interestingly, in the 34a-bound structure, the
piperidine N-Me is located in close proximity to V313 (Fig. 9). In an
attempt to further understand the KDM5B-preferring activity of
Fig. 9. Overlay of crystal structures of 34a (blue) and 16a (beige) bound to KDM4A. Zn(II) atoms are shown as spheres. Protein backbone chains are represented as cartoon tubes, key
residues are displayed in line representation. Compounds 34a and 16a are shown in ball and stick representation. (For interpretation of the references to colour in this figure legend,
the reader is referred to the Web version of this article.)
Fig. 8. Overlay of crystal structures of 19d (pink) and 16a (beige) bound to KDM4A. Zn(II) are shown as spheres. Proteins backbone chains are represented as a cartoon tubes, key
residues are displayed in line representation. Compounds 19d and 16a are shown in ball and stick representation. (For interpretation of the references to colour in this figure legend,
the reader is referred to the Web version of this article.)
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KDM5B (Fig. S5). Given the higher potency of 34a against KDM5B
relative to KDM4A, we were surprised to find that the electron
density corresponding to the C4-pyrazole substituent was less well
resolved in the 34a-KDM5B structure, with no interpretable den-
sity for the piperidine N-Me group (Fig. S5). Furthermore, no
interaction was observed with the carboxylic acid of residue D502
(D191 in KDM4A). Analogous to the 34a-KDM4A structure, residue
W486 in KDM5B (Y175 in KDM4A) and surrounding loops adopt
the Apo conformation (Fig. 3 and Fig. S5). However, the piperidine
ring of 34amakes a hydrophobic interaction with W486 in KDM5B
but does not form productive interactions with the equivalent Y175
residue in the 34a-KDM4A crystal structure this may account for
the KDM5B-preferring activity profile of 34a.
Recognising the KDM5B-preferring inhibitory profile of 34a
(Table 5), the close proximity of the N-Me group of 34a to V313,
V171 and I168 in KDM4A (Fig. 9) prompted us to introduce bulkier
N-alkyl substituents to improve lipophilic contact with these resi-
dues, aiming for an enhancement in KDM4 potency. This hypoth-
esis led to the synthesis of compounds 34b-h (Table 5); however,
most of these analogues displayed only a modest gain in KDM4
inhibitory activity relative to 34a, with KDM5 inhibition also
maintained (Table 5). Weaker inhibition of the other KDM sub-
families was observed; for example, 34f displayed inhibition of
KDM2A (IC50¼12.54 mM), KDM3A (IC50¼ 6.13 mM), and KDM6B
(<60% inhibition at 100 mM).
In an attempt to rationalise the KDM4/5 structure activity
relationship (SAR) observations in this subseries, we determined
the crystal structures of 34b and 34g in complex with KDM4A
(Fig. 10A and B, respectively). In both cases, the C4-pyrazole sub-
stituent is shifted from the position observed in the 34a-bound
KDM4A structure and the interaction between the piperidine ni-
trogen and D191 is no longer present. Notably, the pyrazole C4-
substituents of both 34b and 34g are closer to Y175 and we
observe both apo and ligand-induced shifts in the positions of Y175
and nearby loop 161e170. The terminal carbon of the N-ethylFig. 10. A: Overlay of crystal structures of 34a (blue) and 34b (green) bound to KDM4A. Cha
show exactly the same conformation for the ligand and its neighbouring protein residues. B
and D of the asymmetric unit are shown for 34g-KDM4A structure, as they do not show e
Protein backbone chains are represented as cartoon tubes, key residues are displayed in l
methyl group in 34b has not been modelled due to too weak density linked to the high mob
figure legend, the reader is referred to the Web version of this article.)substituent of 34b is not associated with any electron density in the
four chains of the asymmetric unit, and the N-cyclopentane sub-
stituent in 34g is seen in only two chains; furthermore, interaction
with the three targeted residues V313, V171 and I168 is not
observed. Thus, a piperidine N-substituent bigger than the methyl
is sufficient to disrupt the interaction with D191, likely because of
steric clashes with the side chain of V313 or the main chain
carbonyl of E169 (both of which lie in close proximity to the N-Me
of 34a, Fig. 9). These factors may explain the modest potency
improvement for compounds 34b-h compared to 34a. We also
solved the structures of 34f and 34g bound to KDM5B, which were
nearly identical to the KDM5B-34a structure (Fig. S6), with the
exception of an extra carbon seen for the piperidine N-substituent
of 34f. These structures indicate that the piperidine N-substituents
of 34f and 34g are mobile, and not making specific interactions
with the protein, which likely explains the relatively flat SAR for
this series of compounds against KDM5B. Based on the above ob-
servations, this subseries was not pursued further.
Overall, our investigations towards selective KDM4 over KDM5
inhibition by targeting residue differences between the histone
substrate binding sites afforded potent dual inhibitors of both
KDM4 and KDM5 subfamilies in biochemical assays with selectivity
versus KDM2A, KDM3A, and KDM6B exemplars of other histone
demethylase subfamilies. We have previously reported the KDM
cellular profiling of 16a, and that the KDM inhibitory activity of 16a
is dependent upon the 2OG co-substrate concentration in a
biochemical assay [38]. We therefore assessed the 2OG-depen-
dence of KDM inhibitory activity for exemplar compounds 16m
(Fig. S7), 19a (Fig. 11), and 34f (Fig. S7). For 19a, we observe a 147-
fold drop in KDM4A inhibition with increasing 2OG concentration
from 0.25 mM to a physiologically relevant concentration of 1mM
(Fig. 11) [39e41]. Calculated Ki values [42] (Table 6) demonstrate
similar affinity for KDM4A and KDM5B (16a, Ki¼ 0.003 and
0.002 mM, respectively; 19a, Ki¼ 0.004 and 0.007 mM, respectively).
In addition to co-substrate competition, the translation of
biochemical inhibitory activity into cellular target engagement canins A and B of the asymmetric unit are shown for 34b-KDM4A structure, as they do not
: Overlay of crystal structures of 34a (blue) and 34g (pink) bound to KDM4A. Chains B
xactly the same conformation of the protein. Zn(II) atoms are shown as grey spheres.
ine representation. Compounds are shown in ball and stick representation. The distal
ility of the corresponding atoms. (For interpretation of the references to colour in this
Fig. 11. 2OG co-substrate competition studies for 19a in KDM4A, KDM4B and KDM5B biochemical assays.
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time. Furthermore, biochemical KDM-subfamily selectivity trends
may not be maintained in a cellular environment due to differences
in the affinity of KDM subfamilies for 2OG [28,34], and differences
in the KDM expression levels in cells [28]. We therefore investi-
gated the cellular target engagement of selected compounds
against KDM4A, KDM4B, and KDM5B using two orthogonal assay
formats. Firstly, an InCELL Hunter™ assay based upon measuring
compound-mediated protein stabilisation [43]; secondly, a previ-
ously reported immunofluorescence-based (IF) assay whereby
cellular KDM4A and KDM5B inhibition is determined by moni-
toring the levels of H3K9Me3 and H3K4Me3 histone marks,
respectively [38]. Testing of the known selective KDM5-subfamily
inhibitor 6 in both the InCELL Hunter™ and IF assays provided
KDM5B EC50 values of 0.3 and 0.6 mM, respectively, entirely
consistent with previously reported KDM5 EC50 value of 0.34 mM,Table 6
KDM4A and KDM5B Ki values; KDM4A/B and KDM5B target engagement in cells (InCELL
Compd Ki, (mM) KDM4, EC50 (mM
KDM4A KDM5B KDM4B,
InCELL
Hunter™
16a 0.003 0.002 1.0± 0.7
16b 0.004 0.003 2.0± 0.2
16h 0.003 0.001 1.4± 0.2
16m 0.002 0.001 3.0± 1.6
17f 0.004 0.004 3.5± 0.6
19a 0.004 0.007 1.3± 0.3
19d 0.005 0.002 1.7± 0.6
34f 0.026 0.016 9.1± 2.3
a EC50 data are mean values of at least two independent determinations unless specifi
b Results from a single experiment.based on assessment of H3K4Me3 levels in PC9 cells [31].
We initially tested compounds in the InCELL Hunter™ assay for
KDM4B and KDM5B cellular target engagement with several
compounds demonstrating EC50 values close to 1 mM (Table 6).
Interestingly, compounds 16h, 16m and 17f (Tables 1 and 2), that
display low permeability in the Caco-2 assay, showed cellular target
engagement suggesting cellular internalisation under the assay
conditions. We also profiled compounds in the cellular IF assay
(Table 6). Both 19a and 19d inhibited KDM4A demethylase activity
in cells (EC50¼ 4.7 and 5.9 mM, respectively), slightly more potently
in comparison to KDM5B inhibition (EC50¼13.4 and 20.8 mM,
respectively; Table 6). Consistent with our in vitro biochemical 2OG
competition experiments, we observe a 1175-fold drop in KDM4A
biochemical potency to IF cell-based activity for 19a, a trend that is
replicated across all compounds tested (Table 6). Of note, the
cellular KDM4A and KDM4B EC50 values for 19a (Table 6) are similarHunter™ and IF assays)a.
) KDM5B, EC50 (mM)
KDM4A,
IF assay
InCELL Hunter™ IF assay
8.5± 6.1 0.6± 0.2 24.2± 16.4
not tested 2.9± 1.0 not tested
10.4b 1.1± 0.3 26.0b
30.3± 23.8 1.4± 0.3 3.77b
not tested 1.9± 0.6 not tested
4.7± 3.6 4.0± 3.5 13.4± 8.5
5.9b 1.1± 0.5 20.8b
38% at 200 mM 6.6± 5.0 26.4± 4.4
ed otherwise.
Fig. 12. KDM4A and KDM5B target engagement in HeLa cells by 19a and its matched pair inactive control 41 based on modulation of the relevant histone methyl mark (IF assay).
Constructs encoding FLAG-tagged wild type KDM4A or catalytically inactive mutant (H188A/E190A) KDM4A, and wild type KDM5B or catalytically inactive mutant (H499A/E501A)
KDM5B were used.
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physiologically relevant 2OG concentration (approximately 1mM)
[39e41] (IC50¼ 2.21 mM, and 0.79 mM, respectively, Fig. 11). As a
further confirmation of cell-based activity, 19a was tested in the IF
assay alongside its matched pair inactive control 41 (KDM4A,
KDM4B and KDM5B in vitro biochemical IC50> 15 mM) (Scheme 6,
Fig. 12). In this assay format, we created an assay window through
overexpression of the catalytically active protein since we were
unable to measure changes in endogenous methyl marks. The
mutant protein used in the assay is catalytically dead; as such,
addition of an inhibitor should have no effect on the methyl marks
providing that no modulation of endogenous methyl marks occurs.
Pleasingly, compound 41 did not alter levels of H3K9Me3 nor
H3K4Me3 histone methyl marks (Fig. 12) suggesting that elevation
of these marks upon incubation of the cells with 19a is due to cell-
based inhibition of KDM4 or KDM5 subfamily enzymes by com-
pound 19a.
Taken together, these studies suggest that the 2-OG competitive
inhibition mode of the C8-substituted pyrido[3,4-d]pyrimidin-
4(3H)-one series is the major contributing factor to the drop off
between in vitro biochemical and cell-based potency, and that a
greater than 10-fold improvement in biochemical KDM4 inhibitory
activity would likely be required to achieve sub-micromolar
cellular KDM4 inhibition. In addition, if the observed tentative
selectivity trends regarding cellular target inhibition are main-
tained, then a 10-fold KDM4 over KDM5 in vitro biochemical
selectivity window may be sufficient to provide a 30-fold KDM4
selective inhibitor in cells.
We have previously reported that aldehyde oxidase (AO)-
mediated metabolism at C2 of the pyridopyrimidinone scaffold
leads to high in vivo clearance for this class of compounds, pre-
cluding their use in in vivo settings [44]. Given these findings, we
investigated the stability of the pyridopyrimidinone derivatives in
cellular cultures in vitro, and found no evidence of cell-based
metabolism. For example, incubation of 19a and its inactive con-
trol 41 in human prostate carcinoma LNCaP cells for up to 120 h
showed uptake of the parent compounds in a time-dependent
manner and stable concentrations in media with no metabolitesdetected in cells or media culture. We further characterised 19a by
measuring its kinetic aqueous solubility (93.3 mM), human plasma
protein binding (89%), and in vitro intrinsic microsomal clearance in
mouse, rat, and human (7.5, 19.8, and 24.7 mL/min/mg,
respectively).
4. Conclusion
Following our discovery of C8-pyridopyrimidinone-based ana-
logues 4 and 16a as selective, dual KDM4 and KDM5 subfamily
inhibitors [29], we determined the crystal structures of 16a in
complex with both KDM4A and KDM5B. Both structures reveal that
the C8-substituent extends towards the histone substrate binding
site and the solvent exposed surface of the enzymes. We identified
residues in close proximity to the m-Cl phenyl moiety of 16a that
are conserved within, but differ between the KDM4 and KDM5
subfamilies. Targeting these residues, in particular E169 and V313
(KDM4A numbering), did not elicit the desired KDM4 over KDM5
selectivity profile in in vitro biochemical assays; likely due to
mobility of the histone peptide binding region of both the KDM4A
and KDM5B proteins, and conformational flexibility of the syn-
thesised ligands. Nevertheless, many compounds displayed potent
and selective KDM4/KDM5 dual inhibition. Conformational
constraint of the pyrazole C4-substituent by direct attachment of
an N-methylpiperidin-4-yl moiety provided 34a, a KDM5-
subfamily preferring inhibitor. Subsequent structure-based design
to increase KDM4 potency for this subseries via optimising lipo-
philic interactions with V313 (KDM4A numbering) proved unsuc-
cessful. In an alternative approach, we rigidified the distal part of
the flexible pyrazole C4-substituent, and optimised interactions
with V313 by introducing a spirocyclic ring systemwhich led to 19a,
a potent, cell-penetrant and selective KDM4/KDM5 dual inhibitor. A
crystal structure of 19a bound to KDM4A confirmed a bindingmode
broadly similar to that of 16a and revealed distinct features
including an induced-fit movement of loop 308e313 of KDM4A
which folds over the phenyl ring of the spirocyclic system to create
a hydrophobic stacking interactionwith both themain chain and Cb
of D311. Compound cellular profiling in two orthogonal target-
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cell-based activity across multiple analogues. Compounds 19a and
19d showed single digit mM KDM4A/KDM4B cellular inhibitory
activity in the two orthogonal cell-based assay formats. Detailed
characterisation of 19a and additional analogues suggests that the
significant drop in potency from in vitro biochemical to cell-based
target engagement assays can be mainly attributed to the 2OG-
competitive mode of inhibition. Taken together, our data suggests
that sub-1nM in vitro biochemical affinity will be required with this
C8-substituted pyridopyrimidinone series in order to achieve sub-
mM target inhibition in cells. Achieving sub-1nM KDM4 biochem-
ical potency, together with KDM5-subfamily selectivity via pyr-
idopyrimidinone C8-derivatisation, is likely to be challenging. The
lessons learned may be applied to a different scaffold to achieve
potent and selective KDM4 inhibition.
5. Experimental section
KDM4A and KDM4B AlphaScreen™ biochemical assays.
KDM4A and KDM4B IC50 values were determined as previously
described [29]. In these assays 2OG co-substrate concentrations
were as follows: KDM4A: 10 mM; KDM4B 2 mM.
KDM5B and KDM5C AlphaScreen™ biochemical assays:
KDM5B and KDM5C IC50 values were determined as previously
described [29]. In these assays 2OG co-substrate concentrations
were as follows: KDM5B: 5 mM; KDM5C: 5 mM.
KDM2A, KDM3A and KDM6B AlphaScreen™ biochemical as-
says. IC50 values were determined as previously described [29] and
references cited therein. In these assays 2OG co-substrate concen-
trations were as follows: KDM2A: 10 mM; KDM3A: 5 mM; KDM6B:
10 mM.
5.1. Cell-based assays for KDM4A/B and KDM5B target engagement
IF assay: Mammalian overexpression constructs encoding full
length 1*FLAG-tagged wild type, or catalytically inactive mutant
(H188A/E190A), KDM4A were obtained from the Structural Geno-
mics Consortium. Constructs encoding wild type or catalytically
inactive mutant (H499A/E501A) KDM5B have been previously
described [38].
HeLa cells (ATCC) were routinely cultured at 37 C, 5% CO2 in
DMEM (Sigma-Aldrich, UK) supplemented with 10% FBS (Gibco,
UK), 1% L-glutamine (Gibco, UK) and 1% non-essential amino acids
(Sigma-Aldrich, UK), and passaged regularly using 0.25% Trypsin-
EDTA (Sigma-Aldrich, UK) before reaching confluence.
For IF, 6000 cells/well were seeded into a 96-well clear bottom
ViewPlate (PerkinElmer, UK) and incubated overnight. DNA over-
expression vectors were transfected into cells using HeLaFect
transfection reagent (OZBIOSCIENCES, France). Briefly, 0.1 mg/well
plasmid DNA and 0.15 mL/well HeLaFect were diluted in separate
tubes containing 25 mL/well OptiMEM (Gibco, UK). The two solu-
tions were gently mixed in a 1:1 ratio and incubated for 20min at
room temperature. Following aspiration of the culture medium, the
DNA-lipid complex was added to cells and incubated for 4 h at
37 C, 5% CO2. Compounds were prepared in culture medium sup-
plemented with 20% FBS and an appropriate volume of DMSO
(Sigma-Aldrich, UK) to maintain solvent concentration. Com-
pounds were serially diluted at a 1:3 to 1:5 dilution ratio to 5X final
concentration in a 96-well plate (ThermoFisher Scientific, UK).
Compound was then added to cells and incubated for a further
24 h at 37 C, 5% CO2. After 24 h compound incubation, cells were
stained for immunofluorescence and analysed as previously
described [38]. Immunofluorescence images of 10 fields of view per
well were captured through a 20 objective on the PerkinElmer IN
Cell 2200 instrument. High-content analysis was performed usingINCell Analyzer software (GE Healthcare, UK), and concentration-
response curves generated in GraphPad Prism 6 (GraphPad, USA)
and Dotmatics (Dotmatics, UK).
InCELL Hunter™ assay: KDM4B and KDM5B cellular target
engagement assays were set up using the InCell Hunter Target
Engagement Kit from DiscoverX (DiscoverX 2018) [43]. For the
KDM4B assay, the expressed protein comprised the N-terminal
region of KDM4B (aa's 1e348) fused upstream of the F24 mutant
(E31G-R71G-K105E) of FKBP1A [45] with an ePL tag (enhanced
ProLabel, DiscoverX) appended at the C-terminus. In the KDM5B
assay, the N-terminal region (aa's 26e772) of the protein fusedwith
a C-terminal ePL tag was used. Constructs were transfected over
24 h in HEK293T cells using Lipofectamine 3000 (ThermoFisher
Scientific). 2.5 103 transfected cells/well were re-plated in 384
assay plates before treating with compounds over 6 h. To complete
the assay, cells were incubated over 30min at RT with the InCell
Hunter assay reagents mix following the manufacturer's in-
structions before reading the chemiluminescent signal.
5.2. Crystal structure determinations
KDM4A structures. A previously established 6His-TEV-KDM4A
construct (residues 1e359) [46] was produced in Escherichia coli
and purified by nickel affinity chromatography, followed by tag
removal with TEV protease, reverse nickel affinity, and gel filtration.
The proteinwas stored at80 C at 10mg/mL in a buffer containing
10mM HEPES pH 7.5 and 200mM NaCl. Purified KDM4A was
crystallized in the apo form at 18 C using the hanging-drop vapor-
diffusion method. The crystallization drops were composed of
1.5 mL of protein (7mg/mL) and 1.5 mL of reservoir solution con-
taining 14% (w/v) PEG4000 and 0.1M BTP pH 7.5, placed over
800 mL of reservoir solution. Plate-like crystals typically grew in a
week at 18 C and were soaked by addition of 0.75 mL of compound
at 50e200mM in DMSO directly to the drops, followed by 4e48 h
incubation at 18 C. Crystals were briefly transferred to cryopro-
tectant solution containing 14% (w/v) PEG4000, 75mM BTP pH 7.5,
and 25% (v/v) glycerol prior to freezing in liquid nitrogen.
KDM5B structures. A previously established 6His-TEV-KDM5B
construct (residues 26-771D101374) [47] was produced in Sf9
cells and purified by nickel affinity chromatography, followed by
tag removal with TEV protease, gel filtration and reverse nickel
affinity. Protein was concentrated to 8mg/mL crystallized at 4 C
using the sitting drop vapor diffusion method. KDM5B was pre-
incubated with 4mM MnCl2 before the protein was transferred to
crystallization plates. Crystals were obtained in drops consisting of
100 nL of protein (8mg/mL), 200 nL of a precipitant consisting of
1.6M Na/K phosphate, 0.1M HEPES pH 7.5, and 20 nL of KDM5B
seeds from crystals obtained from the same condition. Crystals
were grown at 4 C, then compounds were soaked into apo crystals
for 5min at a final concentration of 5mM. Crystals were cry-
oprotected with mother liquor supplemented with 25% ethylene
glycol prior to freezing in liquid nitrogen.
Data collection, processing and refinement: X-ray data were
collected in-house at the Institute of Cancer Research, London, UK,
on a Rigaku FRX-AFC11-VariMax Cu-VHF-Pilatus300K, and at Dia-
mond Light Source, Oxfordshire, UK, on beamlines I02, I03, and I04-
1. Crystals of KDM4A belonged to the space group P 1 21 1 and
diffracted to a resolution between 2.14 and 2.81Å. KDM5B crystals
belonged to the space group P 65 2 2 and diffracted to a resolution
between of 2.14 and 2.3 Å. Datasets were integrated with XDS [48]
and scaled and merged with AIMLESS [49]. Structures were solved
by molecular replacement using PHASER [50,51]with the publicly
available KDM4A and KDM5B structures (PDB codes 2OQ7 and
5A1F, respectively) [46,47] with ligand and water molecules
removed used as molecular replacement models. All
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COOT [52] and refined with BUSTER [53] in iterative cycles. Ligand
restraints were generated with GRADE [54] and MOGUL [55]. The
quality of the structures was assessed with MOLPROBITY [56,57].
The data collection and refinement statistics are presented in
Supporting Information Table S1.
Caco-2 permeability: Caco-2 cellular permeability was deter-
mined as previously described [29].
5.3. Cell uptake experiment and stability of 19a in cellular culture
LNCaP cells (ATCC) were routinely cultured at 37 C, 5% CO2 in
RPMI-1640 (Sigma-Aldrich, UK) supplemented with 10% FBS
(Gibco, UK), and passaged regularly using 0.25% Trypsin-EDTA
(Sigma-Aldrich, UK) before reaching confluence.
For cell uptake and stability experiments, 1.5 105 cells/well
were seeded into 6-well plates (Corning, UK) and incubated for
48 h at 37 C, 5% CO2, before treatment with either 10 mM com-
pound or 0.1% DMSO (Sigma-Aldrich, UK) as vehicle control.
Following 1, 6, 24, 48, 72 and 120 h incubation, media was collected
from cells and immediately frozen at 80 C. Cells were trypsi-
nised, pelleted and then frozen at 80 C until analysis.
Cell and tissue culture media extracts were analysed using a
Dionex Ultimate 3000 UHPLC system coupled to a Thermo Scien-
tific Q Exactive Plus orbitrap mass spectrometer (Thermo Fisher
Scientific Inc., Waltham, USA). Separation of analytes was achieved
using an Acquity UPLC HSS T3 column (1.8 mm, 100 2.1mm)
(Waters, Elstree, UK) at a temperature of 50 C and a binary mobile
phase gradient at a flow rate of 0.4mL/min. Initial LC conditions
comprised 10% solvent A (0.1% formic acid in water), 90% solvent B
(methanol); this was ramped to 95% A at 12min, immediately
returned to initial conditions and held for the remaining 3min of
the method. Sample analysis was by electrospray atmospheric
pressure ionization combined with full scan acquisition in positive
ion mode. The capillary voltage was 3.5 kV; desolvation gas and
capillary temperatures were 450 C and 275 C respectively;
sheath, aux and sweep gas flow rates were 55,15 and 3 respectively.
Full MS/dd-MS2 (full MS scan followed by data dependent MS/MS)
and Full MS/AIF (full MS scan followed by all ion fragmentation)
workflows were used in combination. Identification/presence of
metabolites was undertaken with the aid of the software Com-
pound Discoverer (v2.0.0.303, Thermo Fisher Scientific Inc., Wal-
tham, USA). Raw data files of the incubation time course generated
in the acquisition software Chromeleon (v7.2 SR3 (7553)), Thermo
Fisher Scientific Inc., Waltham, USA) were input into the targeted
workflow.
Chemistry: Commercially available starting materials, reagents
and anhydrous solvents were used as supplied. Flash column
chromatography was performed using Merck silica gel 60
(0.025e0.04mm). Thin layer chromatographywas performed using
Merck Millipore TLC silica gel 60 F254 aluminium sheets and
visualised by UV (254 & 280 nm), iodine and KMnO4. Column
chromatography was also performed on a FlashMaster personal
unit using isolute Flash silica columns or a Biotage Isolera purifi-
cation system using Biotage KP-SNAP cartridges. Ion exchange
chromatography was performed using acidic Isolute Flash SCX-II
cartridges or basic Isolute Flash NH2 cartridges. 1H NMR spectra
were recorded on either a Bruker Avance-500 or Bruker Avance-
400 NMR machine. Samples were prepared as solutions in a
deuterated solvent and referenced to the appropriate internal non-
deuterated solvent peak or tetramethylsilane. Chemical shifts were
recorded in ppm (d) downfield of tetramethylsilane.
LC-MS Analysis. Analysis was performed using an Agilent 1200
series HPLC and diode array detector coupled to a 6210 time of
flight mass spectrometer with dual multimode APCI/ESI source.Method A: Analytical separation was carried out at 40 C on a
Merck Chromolith Flash column (RP-18e, 25 2mm) using a flow
rate of 1.5mL/min in a 2min gradient elution with detection at
254 nm. The mobile phase was a mixture of methanol (solvent A)
and water (solvent B), both containing formic acid at 0.1%. Gradient
elution was as follows: 5:95 (A/B) to 100:0 (A/B) over 1.25min,
100:0 (A/B) for 0.5min, and then reversion back to 5:95 (A/B) over
0.05min, finally 5:95 (A/B) for 0.2min.
Method B: Analytical separation was carried out at 30 C on a
Merck Chromolith Flash column (RP-18e, 25 2mm) using a flow
rate of 0.75mL/min in a 4min gradient elution with detection at
254 nm. The mobile phase was a mixture of methanol (solvent A)
and water (solvent B), both containing formic acid at 0.1%. Gradient
elutionwas as follows: 5:95 (A/B) to 100:0 (A/B) over 2.5min,100:0
(A/B) for 1min, and then reversion back to 5:95 (A/B) over 0.1min,
finally 5:95 (A/B) for 0.4min.
Analysis was also performed on a Waters Acquity UPLC and
diode array detector coupled to a Waters G2 QToF mass spec-
trometer fitted with a multimode ESI/APCI source.
Method C: Analytical separation was carried out at 30 C on a
Phenomenex Kinetex C18 column (30 2.1mm, 2.6u, 100 A) using
a flow rate of 0.5mL/min in a 2min gradient elution with detection
at 254 nm. Themobile phase was a mixture of methanol (solvent A)
and water (solvent B), both containing formic acid at 0.1%. Gradient
elution was as follows: 10:90 (A/B) to 90:10 (A/B) over 1.25min,
90:10 (A/B) for 0.5min, and then reversion back to 10:90 (A/B) over
0.15min, finally 10:90 (A/B) for 0.1min.
Method D: Analytical separation was carried out at 30 C on a
Phenomenex Kinetex C18 column (30 2.1mm, 2.6u, 100 A) using
a flow rate of 0.3mL/min in a 4min gradient elution with detection
at 254 nm. Themobile phase was a mixture of methanol (solvent A)
and water (solvent B), both containing formic acid at 0.1%. Gradient
elution was as follows: 10:90 (A/B) to 90:10 (A/B) over 3min, 90:10
(A/B) for 0.5min, and then reversion back to 10:90 (A/B) over
0.3min, finally 10:90 (A/B) for 0.2min.
Analysis was also performed on a Waters system equipped
with a Waters 2545 binary gradient module, a Waters SQ Detector
2, Waters 2489 UV/visible detector, and a Waters 2424 ELS
detector.
Method E: Analytical separationwas carried out on a Kinetex 5u
EVO C18 column (100mm 3.0mm, 100 A) using a flow rate of
2mL/min in a 3min gradient elution. The mobile phase was a
mixture of 93% H2O, 5% acetonitrile, and 2% of 0.5M ammonium
acetate adjusted to pH 6 with glacial acetic acid (solvent A) and 18%
H2O, 80% acetonitrile, and 2% of 0.5M ammonium acetate adjusted
to pH 6 with glacial acetic acid (solvent B). Gradient elution was as
follows: 95:5 (A/B) 0.35min, 95:5 (A/B) to 5:95 (A/B) over 1min,
5:95 (A/B) over 0.75min, and then reversion back to 95:5 (A/B) over
0.1min and 95:5 (A/B) over 0.8min.
LC-HRMS analysis was performed using either an Agilent 1200
series HPLC and diode array detector coupled to a 6210 time of flight
mass spectrometerwith dualmultimode APCI/ESI source (method B)
or a Waters Acquity UPLC and diode array detector coupled to a
Waters G2QToFmass spectrometer fittedwith amultimode ESI/APCI
source (method D). LC-HRMS method B referenced to caffeine
[MþH]þ 195.087652 or hexakis (2,2-difluroethoxy)phosphazene
[MþH]þ 622.02896 or hexakis(1H,1H,3H-tetrafluoropentoxy)phos-
phazene [MþH]þ 922.009798. LC-HRMS method D referenced to
Leucine Enkephalin fragment ion [MþH]þ 397.1876.
Preparative HPLC (for the purification of 34a) purification was
carried out using a Merck Chromolith column (RP18-e
10 100mm) at ambient temperature using a gradient program;
detectionwas by UVeMS; the flow rate was 10mL/min. The mobile
phase used was A: acetonitrile/water¼ 5/95 with 0.1% NH4HCO3, B:
acetonitrile/water¼ 80/20 with 0.1% NH4HCO3.
Y.-V. Le Bihan et al. / European Journal of Medicinal Chemistry 177 (2019) 316e337 333General Procedure 1 e Suzuki coupling: The boronic acid
pinacol ester (1 equiv.), aryl halide (1 equiv.) and Pd(dppf)
Cl2$CH2Cl2 adduct (0.1 equiv.) were dissolved in a mixture of DME
and aqueous sodium carbonate (1M) in a microwave vial. The vial
was sealed, evacuated and backfilled with N2. The reaction mixture
was heated in themicrowave at 120 C for 45min andmonitored by
LCMS. The reaction mixture was concentrated in vacuo to give the
crude material which was purified by Biotage column chromatog-
raphy (see individual compounds for details of the eluent used).
General Procedure 2 e Dihydropyridine hydrogenation and
Boc deprotection: Pd(OH)2 on carbon (0.4 equiv.) was added to a
solution of dihydropyridine (1 equiv.) in EtOH and hydrochloric
acid (1M) under an atmosphere of N2. The reaction mixture was
then flushed with H2 and stirred at room temperature under an
atmosphere of H2 (2 atm) for 1 h. The reaction mixture was moni-
tored by LCMS. On completion of the reduction, the reaction
mixture was filtered through celite to remove catalyst and
concentrated in vacuo to obtain the crude product. The crude ma-
terial was taken up in THF and hydrochloric acid (1M), stirred at
50 C for 2 h and monitored by LCMS. On completion of the reac-
tion, the reaction mixture was concentrated in vacuo and the res-
idue redissolved in MeOH/CH2Cl2. The crude material was passed
through an SCX-2 cartridge eluting with 1M NH3 in MeOH/CH2Cl2.
The ammoniacal solution was concentrated in vacuo to yield the
product.
General Procedure 3 e Amine displacement of mesylate us-
ing trimethylamine: Triethylamine (2 equiv.) was added to a so-
lution of freshly made (from compound 10) mesylate intermediate
(1 equiv.) and amine (1.2 equiv.) in anhydrous DMF under N2. The
reaction mixture was heated at 50 C for 15 h and monitored by
LCMS. When the reaction had reached completion, the reaction
mixture was diluted in H2O and extracted three times with EtOAc.
The combined organic layers were washed with saturated LiCl so-
lution, saturated brine solution, dried over MgSO4 and concen-
trated in vacuo to give the crude material which was purified by
Biotage column chromatography (see individual compounds for
details of the eluent used).
General Procedure 4 e SEM Deprotection with 6M HCl/THF:
Hydrochloric acid (6M, 60e90 equiv.) was added to a solution of
SEM protected material (1 equiv.) in THF (0.1M). The reaction
mixture was stirred at 50e60 C for between 3 and 8 h and moni-
tored by LCMS. Following completion of the reaction, the reaction
mixture was concentrated in vacuo and purified by Biotage column
chromatography on a KP-NH snap column unless otherwise stated
(see individual compounds for details of the eluent used). The
product obtained from column chromatography was triturated
with Et2O to give the pure product.
General Procedure 5 e Reductive amination: To a microwave
vial was added the required aldehyde (1 equiv.) and corresponding
amine (1.5 equiv.) and the flask purged with argon. Anhydrous 1,2-
dichloroethane (4mL) or dichloromethane was then added, the
mixture stirred to allow dissolution followed by the addition of
sodium triacetoxyborohydride (1.6 equiv.), the vial was capped and
the mixture stirred at room temperature. Once the reaction was
deemed complete by LCMS analysis, the mixture was directly
absorbed onto silica gel and purified by flash column chromatog-
raphy to afford the requisite amine (workup procedure A). Alter-
natively, the mixture was concentrated to afford an amorphous
solid and passed through a plug of silica eluting with 40% MeOH/
CH2Cl2 to afford an oil which was used without further purification
(workup procedure B).
General Procedure 6 e SEM deprotection with HCl/1,4-
dioxane: To a microwave vial was added the SEM protected start-
ing material (1 equiv), 1,4-dioxane (3mL) and distilled water (1mL)
followed by the dropwise addition of HCl in dioxane (4M, 25equiv.). The vial was capped and the mixture stirred at 50

C until
analysis by LCMS indicated complete conversion to the product.
The mixture was then concentrated and passed through an SCX-2
cartridge washing initially with MeOH and then NH3/MeOH. The
basic wash was concentrated and triturated with Et2O to afford a
solid. If necessary the solid was further purified by flash column
chromatography on a SNAP KP-NH column eluting with 0e40%
EtOH/CH2Cl2.
General Procedure 7 e Synthesis of pyrazole-piperidines: 4-
(1H-pyrazol-4-yl)piperidine (1 equiv.) was dissolved in NMP or
DMF over 4 Åmol sieve in an oven-dried flask under a flow of N2.
Appropriate aldehyde (3e4 equiv.) was added to the solution in one
portion and the reaction mixture stirred for 10min - 6 h (see in-
dividual compounds for reaction time) at room temperature. So-
dium triacetoxyborohydride (2e4 equiv.) was then added and the
reaction mixture was stirred at room temperature under N2 for 2 h
and monitored by LCMS. On completion of the reaction, the reac-
tion mixturewas concentrated in vacuo and the residue redissolved
in MeOH/CH2Cl2. The crude material was passed through an SCX-2
cartridge eluting with 1M NH3 in MeOH/CH2Cl2. The ammoniacal
solution was concentrated in vacuo to yield the product.
General Procedure 8 e SNAr displacement: Cesium carbonate
(1.5 equiv.) and the requisite pyrazole (1.1 equiv.) were added to a
microwave vial equipped with a stirrer bar. This was sealed, evac-
uated and flushed with N2. Anhydrous MeCN was added to the vial
and the reaction mixture stirred for 20min under N2 at room
temperature. The cap was then removed, 8-chloro-3-((2-(trime-
thylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one (1
equiv.) was added, the vial resealed, evacuated and flushed with N2.
The reaction mixturewas then stirred at reflux for 18 h. Solids were
removed by filtration and rinsed with CH2Cl2 three times. The
filtrate was concentrated in vacuo to give the crude material which
was purified by Biotage column chromatography (see individual
compounds for details of the eluent used).
5.4. tert-Butyl 4-(3-(pyridin-3-yl)phenyl)-3,6-dihydropyridine-
1(2H)-carboxylate (22h)
According to General Procedure 1, tert-butyl 4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
carboxylate (300mg, 0.970mmol), 3-(3-bromophenyl)pyridine
(227mg, 0.970mmol) and Pd(dppf)Cl2$CH2Cl2 adduct (79mg,
0.097mmol) were reacted together in DME (3mL) and aqueous
sodium carbonate (1M, 2mL). Purification on a KP-Sil snap car-
tridge (9% [0.2M NH3 in MeOH] in CH2Cl2) gave the product as a
brown oil (324mg, quant.); 1H NMR (500MHz, CDCl3) 1.48 (s, 9H),
2.55 (br s, 2H), 3.64 (t, J¼ 5.3 Hz, 2H), 4.08 (s, 2H), 6.08 (br s, 1H),
7.33 (dd, J¼ 7.9, 4.9 Hz, 1H), 7.36e7.45 (m, 3H), 7.53 (s, 1H), 7.84 (dt,
J¼ 7.9, 1.9 Hz, 1H), 8.57 (dd, J¼ 4.8, 1.3 Hz, 1H), 8.82 (br d, J¼ 2.0 Hz,
1H); LC - MS (method C; ESI, m/z) tR ¼ 1.40 mine337 [(M þ H)þ];
HRMS (method D): found 337.1917; calculated for C21H25N2O2
(M þ H)þ 337.1916.
5.5. 3-(3-(Piperidin-4-yl)phenyl)pyridine (25h)
According to General Procedure 2, Pd(OH)2 on carbon (134mg,
0.191mmol) and tert-butyl 4-(3-(pyridin-3-yl)phenyl)-5,6-
dihydropyridine-1(2H)-carboxylate (161mg, 0.479mmol) were
reacted together in EtOH (3mL) and hydrochloric acid (1M, 1mL).
The crudematerial from this reactionwas then stirred in THF (3mL)
and hydrochloric acid (1M, 3mL) and purified by passing through
an SCX-2 cartridge eluting with 1M NH3 in MeOH/DCM. The
ammoniacal solution was concentrated in vacuo to yield the prod-
uct as an off white solid (61.6mg, 54%); 1H NMR (500MHz, CDCl3)
1.69 (qd, J¼ 12.4, 3.7 Hz, 2H), 1.87 (br d, J¼ 12.7 Hz, 2H), 2.08 (br s,
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(br d, J¼ 12.3 Hz, 2H), 7.24e7.29 (m, 1H), 7.34 (ddd, J¼ 7.9, 4.9,
0.8 Hz, 1H), 7.39e7.44 (m, 3H), 7.85 (ddd, J¼ 7.9, 2.2, 1.7 Hz, 1H),
8.57 (dd, J¼ 4.9, 1.7 Hz, 1H), 8.83 (dd, J¼ 2.2, 0.8 Hz, 1H); LC - MS
(method C; ESI,m/z) tR¼ 0.46mine239 [(MþH)þ]; HRMS (method
D): found 239.1555; calculated for C16H19N2 (M þ H)þ 239.1548.
5.6. 8-(4-(2-(4-(3-(Pyridin-3-yl)phenyl)piperidin-1-yl)ethyl)-1H-
pyrazol-1-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]
pyrimidin-4(3H)-one (12h)
According to General Procedure 3, triethylamine (0.03mL,
0.215mmol), 2-(1-(4-oxo-3-((2-(trimethylsilyl)ethoxy)methyl)-
3,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)- ethyl
methanesulfonate (50mg, 0.107mmol) and 3-(3-(piperidin-4-yl)
phenyl)pyridine (38.4mg, 0.161mmol) were reacted together in
anhydrous DMF (1mL). Purification on a KP-Sil snap cartridge (9%
[0.2M NH3 in MeOH] in CH2Cl2) gave the product as a pale yellow
oil (25.4mg, 39%); 1H NMR (500MHz, CDCl3) 0.01 (s, 9H), 0.95e1.01
(m, 2H), 1.86e1.97 (m, 4H), 2.17e2.26 (m, 2H), 2.59e2.67 (m, 1H),
2.69e2.76 (m, 2H), 2.82e2.89 (m, 2H), 3.19 (br d, J¼ 11.2 Hz, 2H),
3.67e3.72 (m, 2H), 5.46 (s, 2H), 7.29e7.32 (m, 1H), 7.36 (dd, J¼ 4.7,
0.7 Hz, 1H), 7.41e7.45 (m, 2H), 7.46 (br s, 1H), 7.81 (br s, 1H), 7.87
(ddd, J¼ 7.9, 2.2, 1.7 Hz, 1H), 8.07 (d, J¼ 5.1 Hz, 1H), 8.31 (s, 1H),
8.57e8.60 (m, 2H), 8.63 (d, J¼ 5.1 Hz,1H), 8.84 (br d, J¼ 2.5 Hz,1H);
LC - MS (method C; ESI, m/z) tR ¼ 1.14 mine608 [(M þ H)þ]; HRMS
(method D): found 608.3162; calculated for C34H42N7O2Si (Mþ H)þ
608.3169.
5.7. 8-(4-(2-(4-(3-(Pyridin-3-yl)phenyl)piperidin-1-yl)ethyl)-1H-
pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one (16h)
According to General Procedure 4, 8-(4-(2-(4-(3-(pyridin-3-yl)
phenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)-3-((2-(trime-
thylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one (16mg,
0.026mmol) and hydrochloric acid (6M, 1mL) were reacted
together in THF (1mL). Purification on a KP-NH snap cartridge (40%
EtOH in CH2Cl2) gave the title product as a white solid (7.8mg,
62%); 1H NMR (500MHz, DMSO‑d6) 1.72e1.86 (m, 4H), 2.10 (td,
J¼ 11.5, 2.5 Hz, 2H), 2.57e2.65 (m, 3H), 2.73 (t, J¼ 7.3 Hz, 2H), 3.10
(br d, J¼ 11.5 Hz, 2H), 7.33 (br d, J¼ 7.7 Hz, 1H), 7.43 (t, J¼ 7.7 Hz,
1H), 7.47 (ddd, J¼ 7.9, 4.7, 0.8 Hz, 1H), 7.53e7.56 (m, 1H), 7.60 (br t,
J¼ 1.6 Hz, 1H), 7.73 (s, 1H), 7.97 (d, J¼ 5.1 Hz, 1H), 8.08 (ddd, J¼ 7.9,
2.3, 1.6 Hz, 1H), 8.29 (s, 1H), 8.44 (s, 1H), 8.54 (d, J¼ 5.1 Hz, 1H), 8.56
(dd, J¼ 4.8, 1.6 Hz, 1H), 8.89 (dd, J¼ 2.3, 0.8 Hz, 1H), 12.80 (br s, 1H);
LC - MS (method C; ESI, m/z) tR ¼ 0.69 min (purity: 100%) e 478
[(M þ H)þ]; HRMS (method D): found 478.2373; calculated for
C28H28N7O (M þ H)þ 478.2355.
5.8. tert-Butyl 4-(4-(pyridin-2-yl)phenyl)-3,6-dihydropyridine-
1(2H)-carboxylate (23a)
According to General Procedure 1, tert-butyl 4-(4,4,5,5-
tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-
carboxylate (300mg, 0.970mmol), 2-(4-bromophenyl)pyridine
(227mg, 0.970mmol) and Pd(dppf)Cl2$CH2Cl2 adduct (79mg,
0.097mmol) were reacted together in DME (3mL) and aqueous
sodium carbonate (1M, 2mL). Purification on a KP-Sil snap car-
tridge (5% [0.2M NH3 in MeOH] in CH2Cl2) gave the product as a
pale brown solid (96mg, 29%); 1H NMR (500MHz, CDCl3) 1.50 (s,
9H), 2.57 (br s, 2H), 3.66 (br t, J¼ 4.9 Hz, 2H), 4.10 (br s, 2H), 6.13 (br
s, 1H), 7.19e7.23 (m, 1H), 7.48 (d, J¼ 8.3 Hz, 2H), 7.71e7.74 (m, 2H),
7.96e7.99 (m, 2H), 8.69 (dt, J¼ 4.9, 1.3 Hz, 1H); LC - MS (method C;
ESI, m/z) tR ¼ 1.44 mine337 [(M þ H)þ]; HRMS (method D): found
337.1916; calculated for C21H25N2O2 (M þ H)þ 337.1916.5.9. 2-(4-(Piperidin-4-yl)phenyl)pyridine (26a)
According to General Procedure 2, Pd(OH)2 on carbon (15.2mg,
0.108mmol) and tert-butyl 4-(4-(pyridin-2-yl)phenyl)-5,6-
dihydropyridine-1(2H)-carboxylate (91mg, 0.271mmol) were
reacted together in EtOH (3mL) and hydrochloric acid (1M,
0.5mL). The crude material from this reaction was then stirred in
THF (2mL) and hydrochloric acid (1M, 2mL) and then purified by
passing through an SCX-2 cartridge eluting with 1M NH3 in MeOH/
CH2Cl2. The ammoniacal solution was concentrated in vacuo to
yield the product as pale yellow oil (46.9mg, 73%); 1H NMR
(500MHz, CDCl3) 1.68 (qd, J¼ 12.5, 3.8 Hz, 2H), 1.87 (br d,
J¼ 12.8 Hz, 2H), 1.99 (br s, 1H), 2.68 (tt, J¼ 12.1, 3.6 Hz, 1H), 2.76 (td,
J¼ 12.1, 2.4 Hz, 2H), 3.21 (br d, J¼ 12.1 Hz, 2H), 7.20 (ddd, J¼ 6.7, 4.8,
1.9 Hz,1H), 7.32e7.35 (m, 2H), 7.69e7.75 (m, 2H), 7.91e7.96 (m, 2H),
8.66e8.69 (m, 1H); LC - MS (method C; ESI,m/z) tR ¼ 0.47 mine239
[(M þ H)þ]; HRMS (method D): found 239.1545; calculated for
C16H19N2 (M þ H)þ 239.1548.
5.10. 8-(4-(2-(4-(4-(Pyridin-2-yl)phenyl)piperidin-1-yl)ethyl)-1H-
pyrazol-1-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]
pyrimidin-4(3H)-one (13a)
According to General Procedure 3, triethylamine (0.05mL,
0.367mmol), 2-(1-(4-oxo-3-((2-(trimethylsilyl)ethoxy)methyl)-
3,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)- ethyl
methanesulfonate (85mg, 0.183mmol) and 2-(4-(piperidin-4-yl)
phenyl)pyridine (43.7mg, 0.183mmol) were reacted together in
anhydrous DMF (1mL). Purification on a KP-Sil snap cartridge (8%
[0.2M NH3 in MeOH] in CH2Cl2) gave the product as a pale yellow
oil (65mg, 58%); 1H NMR (500MHz, CDCl3) 0.01 (s, 9H), 0.96e1.01
(m, 2H), 1.86e1.98 (m, 4H), 2.16e2.27 (m, 2H), 2.57e2.66 (m, 1H),
2.70e2.76 (m, 2H), 2.83e2.90 (m, 2H), 3.20 (br d, J¼ 11.1 Hz, 2H),
3.67e3.72 (m, 2H), 5.46 (s, 2H), 7.21 (ddd, J¼ 6.7, 4.8, 1.6 Hz, 1H),
7.63 (br d, J¼ 8.2 Hz, 2H), 7.70e7.76 (m, 2H), 7.82 (s, 1H), 7.94 (d,
J¼ 8.2 Hz, 2H), 8.07 (d, J¼ 5.0 Hz, 1H), 8.31 (s, 1H), 8.60 (s, 1H), 8.63
(d, J¼ 5.0 Hz, 1H), 8.67e8.69 (m, 1H); LC - MS (method C; ESI, m/z)
tR ¼ 1.17 mine478 [(MSEM þ H)þ]; HRMS (method D): found
478.2351; calculated for C28H28N7O (MSEM þ H)þ 478.2355.
5.11. 8-(4-(2-(4-(4-(Pyridin-2-yl)phenyl)piperidin-1-yl)ethyl)-1H-
pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one (17a)
According to general procedure 4, 8-(4-(2-(4-(4-(pyridin-2-yl)
phenyl)piperidin-1-yl)ethyl)-1H-pyrazol-1-yl)-3-((2-(trime-
thylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one
(25.4mg, 0.042mmol) and hydrochloric acid (6M, 1mL) were
reacted together in THF (1mL). Purification on a KP-NH snap car-
tridge (40% EtOH in CH2Cl2) gave the title product as a white solid
(19.2mg, 96%); 1H NMR (500MHz, DMSO‑d6) 1.72 (qd, J¼ 12.3,
3.3 Hz, 2H), 1.78e1.84 (m, 2H), 2.07e2.14 (m, 2H), 2.54e2.64 (m,
3H), 2.70e2.75 (m, 2H), 3.10 (br d, J¼ 11.0 Hz, 2H), 7.32 (ddd, J¼ 7.4,
4.8, 1.1 Hz, 1H), 7.38 (br d, J¼ 8.3 Hz, 2H), 7.73 (s, 1H), 7.86 (td,
J¼ 7.6, 1.8 Hz, 1H), 7.91e7.94 (m, 1H), 7.98 (d, J¼ 5.1 Hz, 1H), 8.01 (d,
J¼ 8.3 Hz, 2H), 8.29 (s, 1H), 8.45 (s, 1H), 8.54 (d, J¼ 5.1 Hz, 1H),
8.63e8.66 (m, 1H), 12.80 (br s, 1H); LC - MS (method C; ESI, m/z)
tR ¼ 0.72 min (purity: >98%) e 478 [(M þ H)þ]; HRMS (method D):
found 478.2356; calculated for C28H28N7O (M þ H)þ 478.2355.
5.12. 8-(4-(2-(2,3-Dihydrospiro[indene-1,40-piperidin]-10-yl)ethyl)-
1H-pyrazol-1-yl)-3-((2-(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]
pyrimidin-4(3H)-one
According to general procedure 3, triethylamine (0.03mL,
0.237mmol), 2-(1-(4-oxo-3-((2-(trimethylsilyl)ethoxy)methyl)-
Y.-V. Le Bihan et al. / European Journal of Medicinal Chemistry 177 (2019) 316e337 3353,4-dihydropyrido[3,4-d]pyrimidin-8-yl)-1H-pyrazol-4-yl)- ethyl
methanesulfonate (80mg, 0.172mmol) and 2,3-dihydrospiro
[indene-1,40-piperidine] (38.6mg, 0.206mmol) were reacted
together in anhydrous DMF (1mL). Purification on a silica column
eluting with 3% [7M NH3 in MeOH] in CH2Cl2 gave the product as a
pale yellow oil (42mg, 44%); 1H NMR (500MHz, CDCl3) 0.02 (s, 9H),
0.96e1.01 (m, 2H), 1.63 (d, J¼ 12.4 Hz, 2H), 1.99e2.03 (m, 4H), 2.34
(br s, 2H), 2.78 (br s, 2H), 2.87e2.95 (m, 4H), 3.09 (br s, 2H),
3.68e3.74 (m, 2H), 5.48 (s, 2H), 7.16e7.26 (m, 4H), 7.82 (s, 1H), 8.07
(d, J¼ 5.1 Hz,1H), 8.32 (s,1H), 8.61 (s,1H), 8.64 (d, J¼ 5.1 Hz,1H); LC
- MS (method C; ESI, m/z) tR ¼ 1.25 mine557 (M þ H)þ.5.13. 8-(4-(2-(2,3-Dihydrospiro[indene-1,40-piperidin]-10-yl)ethyl)-
1H-pyrazol-1-yl)pyrido[3,4-d]pyrimidin-4(3H)-one (19a)
According to general procedure 4, 8-(4-(2-(2,3-dihydrospiro
[indene-1,40-piperidin]-10-yl)ethyl)-1H-pyrazol-1-yl)-3-((2-(trime-
thylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one (42mg,
0.075mmol) and hydrochloric acid (6M, 1mL) were reacted
together in THF (1mL) for 4 h. Purification was achieved by passing
the crude product through an SCX-2 cartridge eluting first with
methanol and then 7N ammonia in methanol. Fractions containing
the product were combined, concentrated in vacuo, and the residue
triturated with Et2O. The beige precipitate was obtained by filtra-
tion, and dried (31mg, 96%). 1H NMR (500MHz, DMSO‑d6): 1.48 (d,
J¼ 12.5 Hz, 2H), 1.86 (td, J¼ 13.2, 4.3 Hz, 2H), 1.98 (t, J¼ 7.3 Hz, 2H),
2.31 (br s, 2H), 2.65e2.80 (m, 4H), 2.85 (t, J¼ 7.3 Hz, 2H), 2.95e3.06
(m, 2H), 7.11e7.21 (m, 4H), 7.75 (s, 1H), 7.99 (d, J¼ 5.1 Hz, 1H), 8.29
(s, 1H), 8.44 (s, 1H), 8.56 (d, J¼ 5.1 Hz, 1H), 12.59 (br s, 1H); HRMS
(method D): tR¼ 1.83min (purity:100%) e found: 427.2233;
calculated for C25H27N6O (M þ H)þ 427.2246.5.14. 1-Ethyl-4-(1H-pyrazol-4-yl)piperidine (32b)
According to General Procedure 7, 4-(1H-pyrazol-4-yl)piperi-
dine (81mg, 0.536mmol) and acetaldehyde (0.1mL, 1.78mmol)
were reacted together in DMF (5mL) for 10min. Sodium tri-
acetoxyborohydride (454mg, 2.14mmol) was then added. On
completion of the reaction, the reaction mixture was concentrated
in vacuo and the residue redissolved in MeOH/CH2Cl2. The crude
material was passed through an SCX-2 cartridge eluting with 1M
NH3 in MeOH/CH2Cl2. The ammoniacal solution was concentrated
in vacuo to yield the crude product that was used in the next step
without further purification.5.15. 8-(4-(1-Ethylpiperidin-4-yl)-1H-pyrazol-1-yl)-3-((2-
(trimethylsilyl)ethoxy)methyl)pyrido[3,4-d]pyrimidin-4(3H)-one
(33b)
According to General Procedure 8, 8-chloro-3-(2-
trimethylsilylethoxymethyl)pyrido[3,4-d]pyrimidin-4-one
(125mg, 0.401mmol), 1-ethyl-4-(1H-pyrazol-4-yl)piperidine
(77.4mg, 0.432mmol) and cesium carbonate (211mg, 0.648mmol)
were reacted together in anhydrous MeCN (3mL). Purification on a
KP-Sil snap cartridge (15% [0.2M NH3 in MeOH] in CH2Cl2) gave the
product as a pale yellow oil (76.8mg, 39%); 1H NMR (500MHz,
CDCl3) 0.00 (s, 9H), 0.95e1.00 (m, 2H), 1.19 (t, J¼ 7.4 Hz, 3H), 1.90
(qd, J¼ 12.3, 2.8 Hz, 2H), 2.02e2.10 (m, 2H), 2.20 (t, J¼ 11.3 Hz, 2H),
2.57 (q, J¼ 7.4 Hz, 2H), 2.63e2.71 (m,1H), 3.14 (br d, J¼ 11.3 Hz, 2H),
3.66e3.71 (m, 2H), 5.46 (s, 2H), 7.79 (s, 1H), 8.06 (d, J¼ 5.0 Hz, 1H),
8.30 (s, 1H), 8.54 (s, 1H), 8.61 (d, J¼ 5.0 Hz, 1H); LC - MS (method C;
ESI, m/z) tR ¼ 1.12 mine455 [(M þ H)þ]; HRMS (method D): found
455.2590; calculated for C23H35N6O2Si (M þ H)þ 455.2591.5.16. 8-(4-(1-Ethylpiperidin-4-yl)-1H-pyrazol-1-yl)pyrido[3,4-d]
pyrimidin-4(3H)-one (34b)
According to General Procedure 4, 8-[4-(1-ethyl-4-piperidyl)
pyrazol-1-yl]-3-(2-trimethylsilylethoxymethyl)pyrido[3,4-d]pyr-
imidin-4-one (38.2mg, 0.084mmol) and hydrochloric acid (6M,
1mL) were reacted together in THF (1mL). Purification on a KP-NH
snap cartridge (40% EtOH in CH2Cl2) gave the title product as a
white solid (23.8mg, 87%); 1H NMR (500MHz, DMSO‑d6) 1.02 (t,
J¼ 7.2 Hz, 3H), 1.58 (qd, J¼ 12.3, 3.4 Hz, 2H), 1.88e1.94 (m, 2H), 1.98
(t, J¼ 11.6 Hz, 2H), 2.35 (q, J¼ 7.2 Hz, 2H), 2.51e2.56 (m, 1H), 2.96
(br d, J¼ 11.6 Hz, 2H), 7.73 (s, 1H), 7.97 (d, J¼ 5.0 Hz, 1H), 8.28 (s,
1H), 8.37 (s, 1H), 8.52 (d, J¼ 5.0 Hz, 1H), 12.70 (br s, 1H); LC - MS
(method C; ESI,m/z) tR ¼ 0.57 min (purity:>98%) e 325 [(Mþ H)þ];
HRMS (method D): found 325.1787; calculated for C17H21N6O
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